Mutated DNA in the Blood Might Predict Disease Progression in Ovarian Cancer Patients Undergoing Chemotherapy

Mutated DNA in the Blood Might Predict Disease Progression in Ovarian Cancer Patients Undergoing Chemotherapy
Predicting a patient’s response to treatment or time to disease progression might be achieved by measuring the fraction of circulating tumor DNA (ctDNA) with mutated TP53, according to the results of a retrospective study. The study, “Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.
Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

Leave a Comment

Your email address will not be published. Required fields are marked *